Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The Hall of Fame rocker, who has been an advocate for teen cancer patients for nearly three decades, visited with children, young adults and their families at Rainbow Babies Hospital on Monday. The Who’s front man toured the Angie Fowler Adolescent & Young Adult Cancer Institute, which was founded in 2012 to better serve young patients while they undergo cancer treatments and following their release. “Teenagers for so long have been overlooked,” said the 73-year-old, still on the road with longtime bandmate Pete Townshend. “Not nearly enough has been done for them.” For years, teenage cancer patients were hospitalized on pediatric floors or placed with older patients. After consulting with doctors researching treatments and recovery, Daltrey understood the need for teens to have a place of their own, where they could recover in surroundings more suited to their interests and maturity level. “The light went on in my head with this one,” said Daltrey, who first got involved with the Teenage Cancer Trust in 1989. “I was in the Who when I was 18 years old and without the support of this age group — adolescents and young adults — our business wouldn’t be there. The music business is built mostly with this age group. It’s an easy way for me to say, ‘Thank you.’” During his visit, Daltrey, whose iconic voice helped make Who songs such as “My Generation,” ″Behind Blue Eyes” and “Won’t Get Fooled Again” anthems for generations of fans, spent time with young cancer patients who have benefited from their time in facilities like the one at Rainbow Babies Hospital. Daltrey quickly connected with several of the teens, who eagerly shared stories of being diagnosed and lengthy hospital stays. He had a warm word, hug or handshake for each of them and was happy to pose for photos. For Adam Kirk, Daltrey’s visit was a chance to meet a rock hero. The 40-year-old’s daughter, Sawyer, has been fighting leukemia for months and Daltrey’s face lit up when he saw the 1½-year-old being carried toward him. Kirk came prepared for his meeting, getting Daltrey to sign a well-worn copy of “Who’s Next,” regarded as the band’s signature album. As he made his way around an outdoor, rooftop garden, Daltrey was approached by another dad who wanted to show his appreciation for the singer’s charitable work. Tyson Stiles presented Daltrey with a musical gift. While his son, Ryver, spent nearly 300 days in the hospital after being born prematurely, Stiles recorded a short album that included songs he wrote about his son’s ordeal. “I wanted you to have a copy,” Stiles said. “Is it any good?” Daltrey asked. “No, it’s terrible,” Stiles quipped as both men laughed. Later, Daltrey donated a guitar signed by him and Townshend that will be permanently displayed in the Fowler Institute’s in-patient unit. Daltrey also shared memories of his previous visits to Cleveland. He and the Who first came to town in 1967. “It’s a lot different than it used to be,” he said. “It was the dirtiest place I’d ever been to in my life. Everything was covered in soot. But Cleveland audiences were some of the best we ever played for.”

A: The Who’s Roger Daltrey visits teenage cancer patients.
****
Q: The story makes it clear that cost of the test is currently speculative (“could cost about $500”) and goes even further to caution that: “Johns Hopkins holds the patent and has not licensed it as yet to a company that would ultimately set the price.” The story makes the two key results of the test quite clear. First, that the 1,005 people tested already had been diagnosed with one of eight common cancers, and the blood test was able to detect cancer in about 70 percent of them. Second, the test was also given to 812 people without cancer and only a false reading for cancer less than 1 percent of the time. Including the additional finding that the test was only able to detect cancer in about 40 percent of the patients with early cancer (ie. stage I) was a thoughtful way of introducing the relevant issue of falsely negative tests. The story does an excellent job of finding an independent source who explains that one of the potential risks of cancer screening tests is either identifying cancers that are not there, or are benign, and can lead to “pointless and potentially dangerous treatments.” The opposite harm is also mentioned; that is, a screening test that erroneously gives a negative result, leading providers to falsely reassure a patient that cancer is not there. Cautious language is used at many points in the story and it does three things quite well. First, it lists the most important limitation of the study: The screening test studied was unable to identify the type of cancer. Second, the implications of both falsely positive and falsely negative tests were explained succinctly and placed in a clinical context that would matter to those undergoing screening. Finally, we were very encouraged by the inclusion of this sentence: “… the researchers will still have to demonstrate that the test improves and extends the lives of cancer patients.” There is no disease mongering in this story. The two independent sources cited provide important context for understanding the strengths, limitations, and clinical context of the screening test. This was a tough call, but ultimately we felt the story would have been stronger had it mentioned the performance of current screening methods for some of the cancer types, such as Cologuard for colon cancer. That said, we were glad the story included some of the pitfalls of screening for prostate and breast cancer, as well as the long struggle to develop more blood tests for cancer. It’s mentioned the authors of the study are “hoping their idea would eventually lead to a $500 test … but they have a long way to go.” Future studies of the screening test are also discussed, so it seems clear this test is not currently available. It’s made clear that “there have been many attempts over the decades to develop blood tests to screen for cancers … but these methods don’t give reliable results.” It’s also pointed out that what makes this screening test unique is that it combines two previously used methods (screening for proteins and for DNA) into one test. This story does not appear to rely upon a news release.

A: Scientists Edge Closer To A Blood Test To Detect Cancers
****
Q: The state’s congressional delegation announced the grant from the Centers for Medicare and Medicaid Services. It’s meant to increase the treatment capacity of Medicaid providers for substance use disorder treatment and recovery services. U.S. Sen. Sheldon Whitehouse, a Rhode Island Democrat, says the funding will help ensure services are there when needed. Whitehouse, who wrote a 2016 law to guide the federal response to the opioid epidemic, says no patient who wants help should be turned away. Behavioral health providers will receive telemedicine services and technical assistance in billing and administration. The grant will also allow Rhode Island to recruit and train new providers. There were 314 overdose deaths in Rhode Island in 2018.

A:
Rhode Island awarded federal funding for addiction treatment.
****